Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
A dense cluster of CEO transitions (Mattel, Heineken, Verra Mobility, Xilam, Brown-Forman, BellRing), board appointments and shareholder-driven governance actions (Al Shams cooperation agreement, Seibu capital allocation push, Kneat and Synaptics sale processes) shows companies using orderly succession and board refreshment to stabilize operations and respond to activist and M&A pressure. Chevron's divestiture of Hess Midstream interests adds a portfolio-simplification theme. The facts are mostly broad corporate-governance events with limited direct AI or fintech content, so the narrative is about governance and succession practice rather than AI-finance.
Companies are moving fast to build AI-native products: Zeta's AthenaOS, AIM chip and MCP launches, AI-driven shopping discovery, and funding and executive hires focused on AI and security. At the same time, OpenAI's capability and safety debates (a safety lead's resignation, agent breakouts, open-source models expected within a year) and warnings that agents need verified identity with financial institutions show that governance and trust are lagging adoption. Regulators and courts are starting to respond, for example through the AI music streaming fraud conviction and California's new rules.
J.P. Morgan's Seth Seifman says A&D stocks were weak in Q3 and sentiment is sour even with the broader market near highs. On Oct. 8 he downgraded Leidos to Neutral, because its low valuation doesn't justify Overweight when other aerospace names offer better upside. He kept Overweight on Boeing ($290 target) and StandardAero ($40), but flagged weaker 2027 Boeing cash-flow expectations. Seifman expects solid Q3 results from most A&D companies, and expects election uncertainty to ease after Nov. 3 but fiscal 2027 budget negotiations to keep the outlook cloudy. Elsewhere, analysts are making similar stock-by-stock calls, including Goldman resuming Iovance at Buy, Seaport initiating Wendy's at Neutral, and Bank of America reiterating Buy on NuScale. The pattern is a market that rewards upward earnings revisions and catalysts, not cheap valuation.
Oncology is moving toward bispecific-plus-ADC combinations (Summit's ivonescimab with AstraZeneca/Daiichi's Datroway) and personalized mRNA cancer vaccines (Merck/Moderna's intismeran). Regulatory and data catalysts cluster in Q4 2026: the ivonescimab BLA PDUFA date of Nov 14, intismeran data at ESMO on Oct 24, and the EXCALIBER-RRMM Phase 3 PFS readout. In parallel, AstraZeneca is pitching AI-designed biologics and 'lab of the future' automation as the way to cut discovery timelines. Capital allocation is uneven. Commercial players such as Novocure and Kiniksa report strong quarters, while smaller ADC developers like ADC Therapeutics cut headcount to stretch cash into 2028.
Biotech is being shaped on two fronts. AI is moving in as funder and policy actor: the OpenAI Foundation made health grants, and Trump named an AI czar and agreed a self-regulation approach with tech executives. Biosecurity concerns also surfaced, as Kimi models were jailbroken to give bioweapon instructions. Meanwhile, sector fundamentals are mixed. Commercial winners such as Eli Lilly's obesity drugs and BioArctic's Leqembi royalties sit beside pre-revenue IND and trial-stage firms, a wave of executive changes (Idorsia, MindWalk), and a few guidance raises (ABL Texcell, VivoSim).
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedWafer Dicing Services Market Set to Exceed US$ 932.9 Million by 2035 | Astute Analytica
“Wafer Dicing Services Market Set to Exceed US$ 932.9 Million by 2035 | Astute Analytica Chicago, Dec…”
AI Diagnostics: The End of the High-Cost Imaging Era
“AI Diagnostics: The End of the High-Cost Imaging Era VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]…”
ChannelCon 2026 Registration Opens: “The Channel Effect” to Take Center Stage in San Diego August 3–5
“ChannelCon 2026 Registration Opens: “The Channel Effect” to Take Center Stage in San Diego August 3–5 OAKBROOK TERRACE, Ill., March 25, 2026 (GLOBE NEWSWIRE) -- Registration is now open for ChannelCon 2026, the Global Technology Industry Association (GTIA)’s premier annual event, which will take place August 3–5, 2026,…”
Credicorp Q4 Earnings Call Highlights
“Credicorp Q4 Earnings Call Highlights Credicorp logo Key Points Credicorp closed 2025 with “record high net income” and strong profitability — ROE 19% for the year and 16.9% in Q4 — while credit metrics improved to a NPL ratio of 4.5%, cost of risk 1.8% and NPL coverage 112.4%…”
$9.8 Billion in Autonomy Spending Hits the AI-Boosted Defense Supply Chain
“$9.8 Billion in Autonomy Spending Hits the AI-Boosted Defense Supply Chain NEW YORK, Feb…”
Silicon Motion Announces Results for the Fourth Quarter and Year Ended December 31, 2025
“Silicon Motion Announces Results for the Fourth Quarter and Year Ended December 31, 2025 Business Highlights Fourth quarter of 2025 sales increased 15% Q/Q and increased 46% Y/Y SSD controller sales: 4Q of 2025 increased 25% to 30% Q/Q and increased 35% to 40% Y/YeMMC+UFS controller sales: 4Q of 2025 increased 0% to 5%…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Adobe's weak guidance, Alphabet's negative free cash flow, and a wave of safety-driven departures from Anthropic, Google and OpenAI show investors and insiders both demanding proof, not promises — even as California moves first to regulate AI's reach into children's lives.
A single summit produced roughly $950 billion in AI infrastructure deals and locked Nvidia into South Korea's memory supply chain, while one research firm says Wall Street is still underpricing the memory chip boom behind it. Here's what's verified, what's just one analyst's call, and what's still speculative.
C3.ai's CEO sold $4.8 million in stock the same week the industry's biggest AI-agent-trust survey turned out unreliable on 11 checked claims, even as Manulife, Box and a wave of banking and healthcare startups commit real budgets. Via News separates the verified from the unverified.
Google now lets users strip visible watermarks from Gemini-made images, video and music — a move that cuts against the story of an industry rushing toward stronger AI-content labeling, and lands the same week OpenAI lost another senior executive.
Nvidia and South Korea's chipmakers signed roughly $950 billion in new AI agreements in July, including a deal to help secure Nvidia's HBM memory supply from SK Hynix, even as chip stocks logged a sharp correction and the Nasdaq 100 hit a 2.75-month low. Via News traces the deals, earnings and balance-sheet data behind the divergence.
A late-July selloff cut deep into AI-chip stocks — Micron fell nearly 40% from its peak — even as Nvidia expanded its SK hynix memory deal, GlobalFoundries signed a $300M federal photonics award, and Skyworks-Qorvo named a combined leadership team. The data show a maturing boom repricing risk, not a broken one.
Nearly all enterprises surveyed say they'll deploy AI agents within two years, but agents can typically reach under half of company data — and as little as 30% at 'data laggard' firms. Platform giants are selling governance; a new wave of startups is skipping the data problem by targeting narrow, auditable back-office tasks instead.
Brad Lightcap, OpenAI's special projects lead and the company's former chief operating officer, has announced his departure from the company.
Insurer Manulife, software firm Box and data platform Snowflake are each rolling out enterprise AI agent tools this year, spanning insurance, content management and data operations worldwide. A fintech startup, Casap, is building agents for dispute resolution, while enterprise leaders across regions report unclear governance for the technology.
Micron and SanDisk are among 2026's top-performing chip stocks on AI memory demand, but both have fallen sharply from June record highs. Figures dated and sourced.
Jeff Dean and Sanjay Ghemawat quit Google within the same week to launch startup Discovery Loop, while Demis Hassabis stepped back from running DeepMind. Alphabet responded by investing in the new venture rather than treating the exits as a pure loss, a hedging strategy now spreading across global AI markets.
Oriol Vinyals, co-leader of Google's Gemini models, has left to co-found Discovery Loop, a new frontier AI venture. The move puts a veteran of one of the world's best-funded AI labs into a startup that must build compute, capital and talent from scratch amid intense global competition.
Bloom Energy signed a $1.7 billion fuel-cell agreement with Nebius AI, one of the largest on-site power deals for AI data centers to date. The company also struck a deal with utility giant AEP and expanded distribution in South Korea, showing on-site generation is now a global bottleneck for AI buildout.
Bloom Energy signed three fuel-cell partnerships in quick succession, led by a $1.7 billion deal with Nebius AI, plus deals with US utility AEP and South Korea's SK Ecoplant and SK Eternix. Analysts say the geographic spread signals a global scramble for AI data center power beyond traditional grid capacity.
A cluster of AI-native drug discovery platforms launched worldwide in early-to-mid 2026, all running on NVIDIA GPU infrastructure. Novo Nordisk's decision to outsource cell therapy research to an AI-native partner signals a broader industry shift from in-house labs to external, GPU-powered specialists.
BlackRock priced a $12.5 billion bond tied to the Meta-BlackRock Texas Data Center Complex at a steep 7.53% yield after weak demand from investors worldwide. Credit-default swaps on major AI-linked firms jumped in tandem, signaling that credit markets globally are pricing AI infrastructure risk far more cautiously than equity markets.
KLA raised its 2026 wafer fabrication equipment forecast to the low-$150 billion range, citing AI chip demand. The California-based supplier also lifted quarterly revenue guidance to $4 billion and its advanced packaging target to $1.1 billion, alongside a 10-for-1 stock split.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.